Abbott Laboratories (NYSE: ABT) is 3.03% higher on its value in year-to-date trading and has touched a low of $91.64 and a high of $121.64 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ABT stock was last observed hovering at around $114.07 in the last trading session, with the day’s loss setting it -0.67%.
Currently trading at $113.40, the stock is -1.86% and -1.12% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.44 million and changing -0.59% at the moment leaves the stock 2.58% off its SMA200. ABT registered 22.13% gain for a year compared to 6-month gain of 7.01%. The firm has a 50-day simple moving average (SMA 50) of $114.6798 and a 200-day simple moving average (SMA200) of $110.54325.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -0.54% loss in the last 1 month and extending the period to 3 months gives it a 7.04%, and is -2.34% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.45% over the week and 1.52% over the month.
Abbott Laboratories (ABT) has around 114000 employees, a market worth around $197.30B and $41.22B in sales. Current P/E ratio is 34.45 and Fwd P/E is 21.98. Profit margin for the company is 13.95%. Distance from 52-week low is 23.75% and -6.77% from its 52-week high. The company has generated returns on investments over the last 12 months (10.96%).
with sales reaching $11.04B over the same period.The EPS is expected to grow by 5.29% this year, but quarterly earnings will post 4.70% year-over-year. Quarterly sales are estimated to grow 7.80% in year-over-year returns.
Abbott Laboratories (ABT) Top Institutional Holders
3559.0 institutions hold shares in Abbott Laboratories (ABT), with institutional investors hold 79.94% of the company’s shares. The shares outstanding are 1.73B, and float is at 1.73B with Short Float at 0.81%. Institutions hold 79.52% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 166.35 million shares valued at $17.29 billion. The investor’s holdings represent 9.5932% of the ABT Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 131.13 million shares valued at $13.63 billion to account for 7.5619 of the shares outstanding. The other top investors are STATE STREET CORP which holds 74.4 million shares representing 4.2903% and valued at over $7.73 billion, while CAPITAL INTERNATIONAL INVESTORS holds 4.1405 of the shares totaling 71.8 million with a market value of $7.46 billion.
Abbott Laboratories (ABT) Insider Activity
The most recent transaction is an insider sale by ALLEN HUBERT L, the company’s EXECUTIVE VICE PRESIDENT. SEC filings show that ALLEN HUBERT L sold 157,421 shares of the company’s common stock on Oct 21 ’24 at a price of $117.04 per share for a total of $18.42 million. Following the sale, the insider now owns 0.18 million shares.
Still, SEC filings show that on Sep 12 ’24, Ford Robert B (CHAIRMAN AND CEO) disposed off 141,679 shares at an average price of $116.41 for $16.49 million. The insider now directly holds 220,059 shares of Abbott Laboratories (ABT).
